Thrombolytic therapy is a treatment that dissolves dangerous blood clots blocking arteries or veins, restoring blood flow to organs like the brain, heart, and lungs. It works by activating your body’s own clot-dissolving system and is most commonly used in emergencies like heart attacks, strokes, and pulmonary embolisms. Because its effectiveness drops sharply with every passing minute, thrombolytic therapy is one of the most time-sensitive treatments in medicine.
How Thrombolytics Dissolve Clots
Your blood already contains an inactive protein called plasminogen that circulates throughout your bloodstream. Thrombolytic drugs work by converting this inactive protein into its active form, plasmin, which acts like a molecular scissors that cuts through fibrin, the mesh-like protein that holds blood clots together. Once fibrin breaks apart, the clot disintegrates and blood flow resumes.
Some thrombolytic drugs act on plasminogen directly, while others work indirectly by first pairing up with plasminogen or plasmin to form a complex that then activates additional plasminogen molecules in the bloodstream. Either way, the end result is the same: a surge of clot-dissolving activity concentrated at the site of the blockage.
Conditions Treated With Thrombolytics
Thrombolytic therapy is used across several serious conditions where a blood clot threatens organ damage or death:
- Acute ischemic stroke: a clot blocks blood flow to the brain
- Heart attack: a clot blocks a coronary artery
- Pulmonary embolism: a clot lodges in the lungs
- Deep vein thrombosis: a large clot forms in a deep vein, usually in the leg
- Acute peripheral arterial occlusion: a clot cuts off blood supply to a limb
- Blocked catheters: clots that form inside long-term IV lines
In rare cases, thrombolytics have also been used off-label for severe frostbite, where tiny blood clots can threaten tissue survival in the fingers and toes.
The Treatment Window
For ischemic stroke, timing is everything. The original landmark trial showed significant benefit when treatment was given within 3 hours of symptom onset. Later studies extended that window to 4.5 hours, and this remained the standard for roughly 20 years. The most recent guidelines from the American Heart Association and American Stroke Association, published in 2026, now recognize that select patients may benefit from thrombolysis even further out, up to 9 hours or in some cases up to 24 hours, if brain imaging shows there is still salvageable tissue.
These extended windows depend on advanced imaging that can detect how much brain tissue is still alive but at risk. For patients who wake up with stroke symptoms and don’t know exactly when symptoms began, imaging can sometimes confirm eligibility for treatment within 4.5 hours of symptom recognition. The core message hasn’t changed, though: earlier treatment leads to better outcomes, and every minute of delay means more brain tissue lost.
For heart attacks, thrombolytics are most effective within the first few hours but can be given up to 12 hours after symptom onset. For pulmonary embolism, the window is generally wider, though treatment is most urgent in patients whose blood pressure is dropping.
IV vs. Catheter-Directed Delivery
There are two main ways to deliver thrombolytics. The most common is intravenous (IV) administration, where the drug is injected into a vein and travels through the bloodstream to reach the clot. This approach is fast to set up and can be started in any emergency department.
The second approach, catheter-directed thrombolysis, involves threading a thin tube through the blood vessels directly to the clot site and delivering the drug locally. This concentrates the medication where it’s needed and uses a lower total dose. A systematic review comparing the two methods in pulmonary embolism patients found that catheter-directed thrombolysis was associated with a 57% lower risk of death, a 56% lower risk of brain bleeding, and a 39% lower risk of major bleeding compared to systemic IV thrombolysis. The tradeoff is that catheter-directed therapy requires specialized equipment and trained interventional specialists, so it isn’t available everywhere.
How Well It Works
The effectiveness of thrombolytic therapy depends heavily on the size and location of the clot. For strokes caused by blockages in large brain arteries, IV thrombolysis alone reopens the vessel about 12% of the time. That sounds low, but when it works, the results are dramatic: nearly 70% of patients whose vessels reopened achieved a good functional outcome, compared to about 32% of those whose vessels stayed blocked.
For large vessel blockages that don’t respond to IV medication alone, doctors can follow up with catheter-based clot retrieval procedures, which achieve reopening rates around 81%. Patients who received this additional treatment had better outcomes than those who didn’t, with about 43% achieving good functional recovery versus 32%.
For heart attacks and pulmonary embolism, thrombolytics are generally more effective at reopening vessels, particularly when given early. In heart attack care, however, thrombolytics have largely been replaced by emergency catheter procedures in hospitals that can offer them quickly.
Risks and Side Effects
The most serious risk of thrombolytic therapy is bleeding, because the same mechanism that dissolves a harmful clot can also interfere with beneficial clotting elsewhere in the body. The most dangerous complication is bleeding inside the brain. In stroke patients, symptomatic brain hemorrhage occurs in roughly 2% to 4% of those treated, with newer agents like tenecteplase showing rates around 1.8% compared to 3.6% with the older standard, alteplase.
Other bleeding risks include bleeding at IV sites, in the gastrointestinal tract, or in the urinary tract. Allergic reactions are possible but uncommon. Blood pressure can also drop during or shortly after treatment.
Who Cannot Receive Thrombolytics
Because of the bleeding risk, several conditions rule out thrombolytic therapy entirely. These absolute contraindications include active bleeding anywhere in the body, a history of bleeding inside the brain, structural abnormalities in the brain, a stroke within the past 3 months, recent brain or spinal surgery, recent head trauma with a skull fracture or brain injury, and any underlying bleeding disorder.
There are also relative contraindications, situations where the risks may outweigh the benefits but treatment isn’t automatically excluded. These include very high blood pressure (above 180/110), recent surgery or invasive procedures, current use of blood thinners, pregnancy, and traumatic CPR. In these cases, doctors weigh the severity of the clot against the bleeding risk on a case-by-case basis.
What Happens After Treatment
Thrombolytic therapy requires close monitoring afterward. The current standard of care calls for vital sign checks and neurological assessments every 15 minutes for the first 2 hours, every 30 minutes for the next 6 hours, and every hour after that. Medical teams are watching for signs of bleeding, particularly any sudden change in neurological function that could signal a brain hemorrhage.
During this monitoring period, you’ll typically stay in an intensive care or stroke unit. Blood pressure is kept below specific targets to reduce bleeding risk. Blood-thinning medications are usually held for at least 24 hours after thrombolytic treatment to avoid compounding the bleeding risk, and a follow-up brain scan is performed before starting any additional clot-prevention therapy.
Newer Agents and Current Trends
Alteplase has been the standard thrombolytic for stroke treatment for decades, given as a weight-based dose (0.9 mg/kg, up to 90 mg) with 10% delivered as a quick injection and the rest infused over 60 minutes. Tenecteplase is increasingly used as an alternative. It’s given as a single injection rather than a prolonged infusion, which makes it faster and simpler to administer. The latest AHA/ASA guidelines now recommend either tenecteplase (at 0.25 mg/kg, up to 25 mg) or alteplase for eligible stroke patients within 4.5 hours. Notably, a higher dose of tenecteplase (0.4 mg/kg) was found to increase brain bleeding risk without improving outcomes and is no longer recommended.
For patients with mild, non-disabling stroke symptoms, such as isolated sensory changes, clinical trials have not shown a benefit from thrombolysis. Current guidelines recommend dual antiplatelet therapy instead for this group. Thrombolysis has also been explored in children aged 28 days to 18 years with confirmed stroke, where it appears safe, though its effectiveness in that population remains uncertain.